Abu Dhabi, UAE – Burjeel Holdings, one of the leading healthcare providers in the MENA region, is proud to announce a strategic partnership with Caring Cross, a U.S.-based advanced therapy development nonprofit, to optimize the manufacturing and delivery of CAR-T cell therapy in the UAE.
This groundbreaking collaboration aims to localize and scale the production of CAR-T therapy — a revolutionary treatment for certain types of blood cancers — with the goal of making it more affordable, accessible, and eco-friendly for patients across the region.
A New Era of Accessible Advanced Therapies
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of personalized immunotherapy that uses a patient’s own T-cells, genetically modified to target cancer cells. While highly effective, CAR-T therapies are currently associated with high costs and complex logistics, often requiring patients to travel abroad for treatment.
Through this collaboration, Burjeel and Caring Cross aim to:
Establish local CAR-T manufacturing capabilities using decentralized and automated systems to streamline production and reduce costs.
Train and empower regional clinicians and researchers to deliver these therapies safely and effectively.
Accelerate clinical trials and R&D efforts to develop new CAR-T applications tailored to the region’s needs.
Sustainable Biotech Innovation
In addition to enhancing patient access, this partnership reflects a shared commitment to sustainable healthcare innovation. By building local infrastructure for advanced therapies:
The environmental impact of transcontinental shipping of patient samples and treatments is significantly reduced.
Energy-efficient, scalable bioprocessing technologies are being prioritized to lower the carbon footprint of cell therapy manufacturing.
Medical waste is minimized through streamlined and automated processes.
Quotes from Leadership
"This collaboration marks a pivotal moment for healthcare in the UAE," said Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings. "Together with Caring Cross, we are transforming cancer care by making the most advanced treatments both locally available and environmentally responsible."
"Our goal is to democratize access to curative therapies," added Dr. Boro Dropulić, Executive Director of Caring Cross. "By working with Burjeel Holdings, we’re creating a model that merges innovation, equity, and sustainability — one that can be replicated globally."
About Burjeel Holdings:
Burjeel Holdings is a premier private healthcare services provider in the UAE and MENA region, offering world-class patient care, cutting-edge research, and continuous innovation.
About Caring Cross:
Caring Cross is a mission-driven biotechnology organization dedicated to enabling broad access to advanced therapies through sustainable, decentralized manufacturing models and global partnerships.
Post a Comment